ICONIK Labs allows visualisation, analysis and reporting on laboratory data in real time
ICON plc, (NASDAQ: ICLR) a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced ICONIK Labs, the latest service to leverage its ICONIK technology platform.
ICONIK Labs is an interactive analytics tool that allows Clinical and Medical team members to visualise, analyse and report on large volumes of laboratory data in real time. Using ICONIK Labs’ advanced visualisation capabilities, project teams can interact with data and view trends at any level of detail, including patient, site, study or across an entire program through a series of dynamic filters. ICONIK Labs enhances a study’s quality by instantly identifying sites with an unusual number of lab values outside the normal range and can also improve patient safety by providing Hy’s Law analysis which assists with the detection of subjects at risk of Drug Induced Liver Injury (DILI).
Commenting on the new service, Dr. Steve Cutler, Group President, ICON Clinical Research Services, said: “ICONIK Labs has transformed how study teams review and analyse laboratory data and has enabled a fresh approach to combining lab parameters to review study trends. It enables study teams to quickly uncover actionable insights that support earlier, more informed decision-making and more efficient trial management.”
ICONIK Labs is the latest service to leverage the ICONIK technology platform and follows ICON’s recent announcement of ICONIK Monitoring and ICONIK Patient Safety. ICONIK Monitoring is a new service that improves quality and reduces the costs of clinical development through more effective use of monitoring resources. ICONIK Patient Safety enables real-time analysis of aggregated patient safety data, giving study teams the ability to uncover potential medical issues in real-time.
Zenocutuzumab Shows Durable Efficacy in NRG1 Fusion-Positive Cancers in Phase II eNRGy Trial
February 13th 2025The Phase II eNRGy trial showed durable antitumor activity with zenocutuzumab (Bizengri) in patients with NRG1 fusion–positive cancers, particularly non-small cell lung cancer and pancreatic cancer.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
SCOPE Summit 2025: Enhancing the Patient Experience Through Site Centricity
February 12th 2025In an interview with ACT senior editor Andy Studna at SCOPE Summit, Ashley Davidson, vice president, product lead - sponsor tech strategy, Advarra, highlights the need for more site-centric approaches in study startup.